Literature DB >> 28298551

High hypothetical interest in physician-assisted death in multiple sclerosis.

Ruth Ann Marrie1, Amber Salter2, Tuula Tyry2, Gary R Cutter2, Stacey Cofield2, Robert J Fox2.   

Abstract

OBJECTIVE: To assess the opinions of persons with multiple sclerosis (MS) regarding physician-assisted death (PAD).
METHODS: We surveyed participants in the North American Research Committee on Multiple Sclerosis (NARCOMS) Registry regarding PAD. For each of 5 hypothetical situations, respondents indicated whether they definitely would, probably would, probably would not, or definitely would not consider PAD. They also reported their sociodemographics, disability status using Patient-Determined Disease Steps, depression status, pain status, religiosity, and degree of social support. Using multivariable logistic regression models, we evaluated the factors associated with an individual reporting that he or she would definitely or probably consider PAD in each situation.
RESULTS: Of 7,534 respondents, 6,011 (79.8%) were female, and 6,884 (92.9%) were white. Their mean (SD) age was 59.9 (10.2) years. Fifty percent of respondents reported at least moderate disability. Of the 6,792 respondents who responded to any of the PAD questions, 6,400 responded to all questions. Of these, 458 (7.1%) indicated that they would definitely consider PAD in all of the situations listed, while 1,275 (19.9%) indicated that they definitely would not consider PAD in any of the situations listed. If experiencing unbearable pain, 4,383 (65.3%) of respondents would definitely or probably consider PAD. On multivariable analysis, religiosity, social support, depression, pain, disability, sex, and race were associated with considering PAD in some or all of the situations presented.
CONCLUSIONS: Depending upon the situation, a large proportion of persons with MS would consider PAD. The association of depression with considering PAD emphasizes the importance of diagnosing and treating depression.
© 2017 American Academy of Neurology.

Entities:  

Mesh:

Year:  2017        PMID: 28298551     DOI: 10.1212/WNL.0000000000003831

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  7 in total

1.  Uptake and Attitudes About Immunizations in People With Multiple Sclerosis.

Authors:  Ruth Ann Marrie; Leanne Kosowan; Gary R Cutter; Robert Fox; Amber Salter
Journal:  Neurol Clin Pract       Date:  2021-08

2.  Disparities in Telehealth Care in Multiple Sclerosis.

Authors:  Ruth Ann Marrie; Leanne Kosowan; Gary Cutter; Robert Fox; Amber Salter
Journal:  Neurol Clin Pract       Date:  2022-06

3.  Attitudes toward coronavirus disease 2019 vaccination in people with multiple sclerosis.

Authors:  Ruth Ann Marrie; Casandra Dolovich; Gary R Cutter; Robert J Fox; Amber Salter
Journal:  Mult Scler J Exp Transl Clin       Date:  2022-05-22

Review 4.  Comprehensive Approach to Management of Multiple Sclerosis: Addressing Invisible Symptoms-A Narrative Review.

Authors:  Lynsey Lakin; Bryan E Davis; Cherie C Binns; Keisha M Currie; Mary R Rensel
Journal:  Neurol Ther       Date:  2021-04-20

5.  Comparing the MSIS-29 and the Health Utilities Index Mark III in Multiple Sclerosis.

Authors:  Ruth Ann Marrie; Casandra Dolovich; Gary R Cutter; Robert J Fox; Amber Salter
Journal:  Front Neurol       Date:  2021-12-17       Impact factor: 4.003

6.  Functional gastrointestinal disorders negatively affect health-related quality of life in MS.

Authors:  Ruth Ann Marrie; Stella Leung; Tuula Tyry; Gary R Cutter; Robert Fox; Amber Salter
Journal:  Neurol Clin Pract       Date:  2019-10

7.  EAN Guideline on Palliative Care of People with Severe, Progressive Multiple Sclerosis.

Authors:  Alessandra Solari; Andrea Giordano; Jaume Sastre-Garriga; Sascha Köpke; Anne C Rahn; Ingo Kleiter; Katina Aleksovska; Mario A Battaglia; Jette Bay; Massimiliano Copetti; Jelena Drulovic; Liesbeth Kooij; John Mens; Edwin R Meza Murillo; Ivan Milanov; Ron Milo; Tatiana Pekmezovic; Janine Vosburgh; Eli Silber; Simone Veronese; Francesco Patti; Raymond Voltz; David J Oliver
Journal:  J Palliat Med       Date:  2020-05-29       Impact factor: 2.947

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.